Users of bisphosonates, such as Fosamax, have been experiencing the decay or death of their jawbone. Fosamax is prescribed to treat osteoporosis. Last year alone, doctors wrote an estimated 22.4 million prescriptions for Fosamax. Unlike many injuries, osteonecrosis of the jaw is not common in the general population and thus believed to be a "signature" injury that will aid in the prosecution of these cases.
Lawsuits have begun to be filed and the Wall Street Journal ran an article on April 12, 2006 concerning Fosamax and Osteonecrosis.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.